Search Results - "Aftimos, P"

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis by Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., Sotiriou, C.

“…Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative…”
Get full text

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial by Gebhart, G., Lamberts, L.E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W.J.G., Vugts, D.J., Hoekstra, O.S., Schröder, C.P., Menke-van der Houven van Oordt, C.W., Guiot, T., Brouwers, A.H., Awada, A., de Vries, E.G.E., Flamen, P.

“…Only human epidermal growth factor receptor (HER)2 status determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has been…”
Get full text

Liquid biopsy accelerates precision medicine by Amato, O., Aftimos, P., Ignatiadis, M.

Get full text

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer by Bardia, A., Tolaney, S.M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., Hamilton, E., Sharma, P., Recalde, S., Gil, E.C., Traina, T., O’Shaughnessy, J., Cortes, J., Tsai, M., Vahdat, L., Diéras, V., Carey, L.A., Rugo, H.S., Goldenberg, D.M., Hong, Q., Olivo, M., Itri, L.M., Hurvitz, S.A.

“…The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen…”
Get full text

Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all? by Hilbers, F.S., Aftimos, P.

Get full text

Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs by Fadoukhair, Z, Zardavas, D, Chad, M A, Goulioti, T, Aftimos, P, Piccart, M

“…Breast cancer (BC) has been classified into four intrinsic subtypes through seminal studies employing gene expression profiling analysis of primary tumours,…”
Get full text

The AURORA initiative for metastatic breast cancer by Zardavas, D, Maetens, M, Irrthum, A, Goulioti, T, Engelen, K, Fumagalli, D, Salgado, R, Aftimos, P, Saini, K S, Sotiriou, C, Campbell, P, Dinh, P, von Minckwitz, G, Gelber, R D, Dowsett, M, Di Leo, A, Cameron, D, Baselga, J, Gnant, M, Goldhirsch, A, Norton, L, Piccart, M

“…Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused…”
Get full text

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study by Joris, S., Denys, H., Collignon, J., Rasschaert, M., T’Kint de Roodenbeke, D., Duhoux, F.P., Canon, J.-L., Tejpar, S., Mebis, J., Decoster, L., Aftimos, P., De Grève, J.

“…The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance…”
Get full text

First-in-human, first-in-class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors by Calvo, E, Aftimos, P G, Azaro, A, de Miguel, M J, Jungels, C, Zeron-Medina Cuairan, J, Nuciforo, P G, Ehmer, P, Martin, A, Bender, H K, Dembowsky, K

Get full text

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials by Mau-Sorensen, M., van Bussel, M., Kuipers, M., Nielsen, D.L., Verheul, H.M., Aftimos, P., de Jonge, M.J.A., van Triest, B., Falkenius, J., Debus, J., Troost, E., Samuels, M., Sarholz, B., Budach, V., Goel, S., Locatelli, G., Geertsen, P.F.

Get full text

SP-0207 INCIDENTS IN MEDICAL ONCOLOGY: MANAGEMENT AND CLINICAL IMPACT by Aftimos, P, Awada, A

Get full text

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer by Awada, A.H., Boni, V., Moreno, V., Aftimos, P., Kahatt, C., Luepke-Estefan, X.E., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Tabernero, J.

“…Preclinical studies showed a synergistic effect for 5-fluorouracil and lurbinectedin against solid tumors. This phase I trial evaluated a combination of…”
Get full text

Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial by Hui, R., Pearson, A., Cortes Castan, J., Campbell, C., Poirot, C., Azim, H.A., Fumagalli, D., Lambertini, M., Daly, F., Arahmani, A., Perez-Garcia, J., Aftimos, P.G., Bedard, P., Xuereb, L., Loibl, S., Loi, S., Pierrat, M.-J., Turner, N.C., André, F., Curigliano, G.

Get full text

A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors by Awada, A., Eskens, F.A.L.M., Robbrecht, D.G., Lassen, U.N., Sorensen, M., Schellens, J.H.M., de Groot, J.S., Jungels, C., Aftimos, P.G., Fretland, S.O., Thorsson, L., Guren, T.K.

Get full text

Clinical utility of complex multi-platform profiling in metastatic cancer patients by Garcia Foncillas, J., Aftimos, P.G., Barthelemy, P., Bellmunt, J., Berchem, G., Camps, C., de las Peñas, R., Finzel, A., Hervonen, J.P., Joensuu, T., Kong, A., Mackay, J., Mikropoulos, C., Mokbel, K., Mouysset, J.-L., Perren, T.-J., Guitti, G., Laes, J.-F.

Get full text

87 INVITED How to Optimise Strategies for Clinical Development of Combinations Based on Targeted Agents? by Awada, A, Aftimos, P

Get full text

108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignancies by Jacobs, J, Zwaenepoel, K, Aftimos, P, Rolfo, C, Rottey, S, de Lendonck, L. Ysebrant, Silence, K, Awada, A, Thibault, A, Pauwels, P

Get full text

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours by Spicer, J, Awada, A, Brunsvig, P, Saunders, A, Olsen, W.M, Nicolaisen, B, Rekdal, O, Laruelle, M, Marjuadi, F, Vakili, J, Aftimos, P, Barthelemy, P, Deva, S, Baurain, J.F

Get full text

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment by Thouvenin, J., Van Marcke, C., Decoster, L., Raicevic, G., Punie, K., Vandenbulcke, M., Salgado, R., Van Valckenborgh, E., Maes, B., Joris, S., Steichel, D. Vander, Vranken, K., Jacobs, S., Dedeurwaerdere, F., Martens, G., Devos, H., Duhoux, F.P., Rasschaert, M., Pauwels, P., Geboes, K., Collignon, J., Tejpar, S., Canon, J.-L., Peeters, M., Rutten, A., Van de Mooter, T., Vermeij, J., Schrijvers, D., Demey, W., Lybaert, W., Van Huysse, J., Mebis, J., Awada, A., Claes, K.B.M., Hebrant, A., Van der Meulen, J., Delafontaine, B., Bempt, I. Vanden, Maetens, J., de Hemptinne, M., Rottey, S., Aftimos, P., De Grève, J.

“…PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim…”
Get full text

P08.03 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES by Brandsma, D., Dieras, V., Altintas, S., Anders, C., Arnedos, M., Gelderblom, H., Soetekouw, P., Jager, A., van Linde, M., Aftimos, P.

“…BACKGROUND: Without active delivery across the blood-brain barrier (BBB), efficacy of doxorubicin in intracranial tumors is limited. Glutathione pegylated…”
Get full text